Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason D Goldman

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
Plos One|March 20, 2010
A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristicsJohn R Koethe, Andrew O Westfall, Dora K Luhanga, et al.
Health Data Science|February 23, 2023
Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep ImmunophenotypingVenkata R Duvvuri, Andrew Baumgartner, Sevda Molani, et al.
AIDS Research and Human Retroviruses|August 30, 2008
Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapyJason D Goldman, Ronald A Cantrell, Lloyd B Mulenga, et al.
Infectious Agents and Cancer|February 12, 2016
Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive personsRachel A Bender Ignacio, Jason D Goldman, Amalia S Magaret, et al.
Cell Reports|March 1, 2024
Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancerDaniel G Chen, Jingyi Xie, Jongchan Choi, et al.
The New England Journal of Medicine|April 1, 2020
Covid-19 in Critically Ill Patients in the Seattle Region - Case SeriesPavan K Bhatraju, Bijan J Ghassemieh, Michelle Nichols, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 3, 2024
SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk AdultsMatthew E Levy, Evanette Burrows, Vanessa Chilunda, et al.
The Lancet. Respiratory Medicine|September 4, 2021
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialVincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, et al.
The Journal of Infectious Diseases|July 19, 2024
Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 VariantMatthew E Levy, Vanessa Chilunda, Richard E Davis, et al.
Frontiers in Immunology|March 4, 2025
XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variantsMatthew E Levy, Vanessa Chilunda, Phillip R Heaton, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Plos One|March 20, 2010
A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristicsJohn R Koethe, Andrew O Westfall, Dora K Luhanga, et al.
Health Data Science|February 23, 2023
Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep ImmunophenotypingVenkata R Duvvuri, Andrew Baumgartner, Sevda Molani, et al.
AIDS Research and Human Retroviruses|August 30, 2008
Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapyJason D Goldman, Ronald A Cantrell, Lloyd B Mulenga, et al.
Infectious Agents and Cancer|February 12, 2016
Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive personsRachel A Bender Ignacio, Jason D Goldman, Amalia S Magaret, et al.
Cell Reports|March 1, 2024
Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancerDaniel G Chen, Jingyi Xie, Jongchan Choi, et al.
The New England Journal of Medicine|April 1, 2020
Covid-19 in Critically Ill Patients in the Seattle Region - Case SeriesPavan K Bhatraju, Bijan J Ghassemieh, Michelle Nichols, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 3, 2024
SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk AdultsMatthew E Levy, Evanette Burrows, Vanessa Chilunda, et al.
The Lancet. Respiratory Medicine|September 4, 2021
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialVincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, et al.
The Journal of Infectious Diseases|July 19, 2024
Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 VariantMatthew E Levy, Vanessa Chilunda, Richard E Davis, et al.
Frontiers in Immunology|March 4, 2025
XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variantsMatthew E Levy, Vanessa Chilunda, Phillip R Heaton, et al.
Pageof 7